News headlines about Spectrum Pharmaceuticals (NASDAQ:SPPI) have trended somewhat positive on Tuesday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Spectrum Pharmaceuticals earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 45.6011936390514 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news stories that may have effected Accern’s scoring:
A number of brokerages have recently issued reports on SPPI. Zacks Investment Research raised Spectrum Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, January 12th. B. Riley initiated coverage on Spectrum Pharmaceuticals in a research note on Monday, December 18th. They issued a “buy” rating and a $26.00 target price for the company. Jefferies Group raised their price target on Spectrum Pharmaceuticals to $25.00 and gave the stock a “buy” rating in a research report on Friday, October 20th. HC Wainwright lifted their target price on Spectrum Pharmaceuticals to $33.00 and gave the stock a “buy” rating in a report on Monday, February 5th. Finally, BidaskClub lowered Spectrum Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 3rd. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $22.83.
Spectrum Pharmaceuticals (NASDAQ SPPI) opened at $20.41 on Tuesday. The firm has a market capitalization of $2,050.00, a P/E ratio of -20.41 and a beta of 1.64. The company has a current ratio of 5.04, a quick ratio of 4.89 and a debt-to-equity ratio of 0.33. Spectrum Pharmaceuticals has a 12-month low of $5.14 and a 12-month high of $23.50.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/02/13/spectrum-pharmaceuticals-sppi-given-news-sentiment-rating-of-0-24.html.
Spectrum Pharmaceuticals Company Profile
Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
Receive News & Ratings for Spectrum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.